News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American Society of Hematology: Benefits Last for Nilotinib in CML, University of Bologna Study


12/7/2010 6:26:08 AM

MedPageToday -- ORLANDO -- The second-generation tyrosine kinase inhibitor nilotinib (Tasigna) had long-lasting benefits in chronic myeloid leukemia with the Philadelphia chromosome, according to the results of a phase II study reported here. After three years of daily treatment with the drug, only one of 73 CML patients had progressed to blast crisis and subsequently died of the disease, said Gianantonio Rosti, MD, of the University of Bologna in Bologna, Italy.

Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES